Fisher Biosciences entered into an expanded polymerase chain reaction (PCR) licensing agreement with Applied Biosystems, under which Fisher Scientific will develop new real-time PCR and PCR-related reagents.

The agreement gives Fisher access to patents not covered in Applied Biosystems’ original licensing program, according to Fisher. The expanded program enables ABgene, a unit of Fisher Biosciences and a licensee under the original program since 1994, to offer optimized reagents and kits for a wide range of PCR and real-time PCR instruments. The new agreement also allows ABgene to develop a broad range of new real-time PCR reagent products and technologies through collaboration with other Fisher Biosciences units, say company officials.

Previous articleEpigenomics Licenses Affymetrix Microarray Technology
Next articleMicroDose Inks Inhaler Technology Deal with Novartis